Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results
February 27 2020 - 8:00AM
Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus
(HBV) therapeutic solutions company, today announced that it has
scheduled its fourth quarter and Year-End 2019 financial results,
conference call and webcast for Thursday, March 5, 2020. The
schedule for the press release and conference call/webcast are as
follows:
• |
Q4 2019 Press Release: |
March 5, 2020 at 7:30 a.m. ET |
• |
Q4 2019 Conference Call: |
March 5, 2020 at 8:45 a.m. ET |
• |
Domestic Dial-In Number: |
(866) 393-1607 |
• |
International Dial-In Number: |
(914) 495-8556 |
• |
Conference ID Number: |
5084457 |
A live webcast of the conference call can be
accessed through the Investors section of Arbutus' website at
www.arbutusbio.com.
An archived webcast will be available on the
Arbutus website after the event. Alternatively, you may access a
replay of the conference call by calling (855) 859-2056 or (404)
537-3406, and reference conference ID 5084457.
About Arbutus
Arbutus Biopharma Corporation is a
publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated
to discovering, developing, and commercializing a cure for patients
suffering from chronic Hepatitis B (HBV) infection. Arbutus is
developing multiple drug candidates, each of which have the
potential to improve upon the standard of care and contribute to a
curative combination regimen. For more information, visit
www.arbutusbio.com.
Contact Information
Investors and MediaWilliam H. Collier President
and CEO Phone: 604-419-3200 Email: ir@arbutusbio.com
Pam Murphy Investor Relations Consultant Phone: 604-419-3200
Email: ir@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Sep 2023 to Sep 2024